WGS
GeneDx Holdings Corp. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -6.2% ·
share flow -4.5% ·
net new positions -6.7%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 88 | -5 | 15.43M | $1.06B | +10 | −14 |
| Q1 2026 | 95 | +2 | 15.21M | $977.50M | +14 | −13 |
| Q4 2025 | 94 | +1 | 15.07M | $1.96B | +3 | −1 |
| Q3 2025 | 16 | -1 | 7.41M | $798.15M | +2 | −4 |
| Q2 2025 | 15 | -1 | 4.67M | $430.80M | +1 | −2 |
| Q1 2025 | 13 | 0 | 2.11M | $186.46M | — | — |
| Q4 2024 | 13 | +1 | 1.90M | $146.41M | +2 | −1 |
| Q3 2024 | 11 | +4 | 1.69M | $71.81M | +4 | — |
| Q2 2024 | 7 | — | 992.14K | $25.94M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 1.43M | — | $132.43M | 0.0% | n/c | 1 | SEC ↗ ×13 |
| 2 | The Vanguard Group ✦ (passive) | 1.18M | — | $109.01M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | Geode Capital Management ✦ (passive) | 484.71K | +23.4% | $44.75M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 4 | State Street Global Advisors ✦ (passive) | 416.00K | +22.5% | $38.40M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Wellington Management ✦ | 406.57K | -4.5% | $37.53M | 0.0% | ▼ Trim | 3 | SEC ↗ ×3 |
| 6 | Citadel Advisors ✦ | 272.23K | +858.7% | $25.13M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 7 | Fidelity (FMR) ✦ | 163.32K | — | $15.08M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 122.75K | +332.9% | $11.33M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 9 | Norges Bank ✦ (passive) | 68.00K | 0.0% | $6.28M | 0.0% | Held | 3 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 52.55K | -81.7% | $4.85M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 23.71K | -5.4% | $2.19M | 0.0% | ▼ Trim | 4 | SEC ↗ ×3 |
| 12 | T. Rowe Price ✦ | 15.05K | +36.7% | $1.39M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 13 | Marshall Wace ✦ | 12.70K | New | $1.17M | 0.0% | New | 1 | SEC ↗ ×2 |
| 14 | D. E. Shaw & Co. ✦ | 9.15K | -97.7% | $845,098 | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 15 | Gotham Asset Management ✦ | 4.49K | -67.3% | $414,841 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $1.17M | 0.0% |
Exited
| Renaissance Technologies | $6.22M | was 0.0% |
| Millennium Management | $1.40M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 240 holders, 31.22M shares, $1.98B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 3.04K sh · $300,846
Officer · 1.08K sh · $106,816
Officer, Director · 1.65K sh · $155,337
Officer, Director · 148 sh · $14,120
Officer, Director · 1.52K sh · $147,774
Officer, Director · 4.14K sh · $406,936
Officer · 586 sh · $55,235
Officer · 52 sh · $4,961
Officer · 541 sh · $52,423
Officer · 1.47K sh · $144,457
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
1.8% of class · View original SEC filing ↗